Novome Biotechnologies, Inc.

Novome Biotechnologies, Inc. is focused on developing and commercializing innovative therapies that leverage microbiome modulation to address gastrointestinal and metabolic disorders, specifically targeting obesity and type 2 diabetes. Founded in 2016 and headquartered in San Francisco, US, Novome Biotechnologies, Inc. specializes in engineered microbial therapies.

The company has undergone a strategic evolution to refine its focus on personalized medicine. The founding team includes Liz Shepherd, Will DeLoache, and Zachary Russ, with Blake Wise serving as CEO. The company raised USD 43. 5 mn in Series B funding on September 13, 2022, led by Tencent Investment and participated by multiple venture firms, raising a total of USD 43.

5 mn to date, with a current valuation of USD 123. 621 mn. Novome Bio focuses on the development and commercialization of innovative therapies in the field of microbiome modulation. Their core product offerings revolve around engineered microbial therapies designed to treat various gastrointestinal and metabolic disorders.

These therapies utilize advanced genetic engineering techniques to create specific strains of bacteria that can target and rectify dysfunctional metabolic pathways. The end-use cases primarily center around improving patient outcomes in disorders such as obesity and type 2 diabetes, with a keen emphasis on personalized medicine. Novome Bio's solutions are strategically positioned in markets across North America and Europe, catering to both healthcare providers and patients who seek effective alternatives to traditional pharmaceutical interventions. Novome Bio generates revenue through a combination of direct-to-consumer sales and partnerships with healthcare providers and research institutions.

The company engages in subscription-based models for access to their proprietary therapies, offering a structured approach that allows clients to utilize their products over a defined period. Transactions typically occur through healthcare networks, where Novome Bio collaborates with clinics and hospitals to integrate their products into treatment plans. Pricing structures for individual services are designed to align with the value provided to patients, especially for their flagship therapeutic offerings, which have been tailored to meet specific health needs. In September 2022, Novome Biotechnologies, Inc.

raised USD 43. 5 mn in Series B funding led by Tencent Investment, with participation from institutional investors. The funding will support the expansion of Novome’s platform capabilities and the ongoing Phase 2a clinical trial for patients with enteric hyperoxaluria, alongside advancing their pipeline of GEMMs candidates for inflammatory bowel disease. The company plans to enhance its product offerings further and is evaluating opportunities to expand into additional health markets across North America and Europe.